Neurologic disorders are among the most common and important clinical manifestations associated with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), mainly those that affect the central nervous system (CNS). Risk of cerebrovascular events in both conditions is increased, and stroke represents one of the most severe complications, with an incidence rate between 3% and 20%, especially in the first five years of diagnosis. This article updates the data regarding the risk factors, clinical manifestations, neuroimaging, and treatment of stroke in SLE and APS.
HolmqvistMSimardJFAsplundKArkemaEV. Stroke in systemic lupus erythematosus: A meta-analysis of population-based cohort studies. RMD Open2015; 1: e000168–e000168.
2.
SaadatniaMSayed-BonakdarZMohammad-SharifiGSarramiAH. Prevalence and prognosis of cerebrovascular accidents and its subtypes among patients with systemic lupus erythematosus in Isfahan Iran: A hospital clinic-based study. Int J Prev Med2014; 5: 123–126.
3.
SaadatniaMSayed-BonakdarZMohammad-SharifiGSarramiAH. The necessity of stroke prevention in patients with systemic lupus erythematosus. J Res Med Sci2012; 17: 894–895.
4.
PetriMThe antiphospholipid antibody syndrome. In: ImbodenJHellmannDStoneJ (eds). Current rheumatology diagnosis & treatment, 2nd ed. USA: Lange Medical Books/McGraw Hill, 2007, pp. 218–221.
5.
TimlinHPetriM. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus2013; 22: 1251–1258.
6.
Fernandez-NebroARúa-FigueroaÍLópez-LongoFJ. Cardiovascular events in systemic lupus erythematosus. A nationwide study in Spain from the RELESSER Registry. Medicine2015; 94: e1183–e1183.
7.
BertsiasGKLoannidisJPAringerM. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: Report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis2010; 69: 2074–2082.
8.
HughesGR. Migraine, memory loss, and “multiple sclerosis.” Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad Med J2003; 79: 81–83.
9.
EsdaileJMAbrahamowiczMGrodzickyT. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum2001; 44: 2331–2337.
10.
BessantRHingoraniAPatelLMacGregorAIsenbergDARahmanA. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford)2004; 43: 924–929.
11.
UrowitzMBGladmanDIbañezD. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus (SLE). Arthritis Care Res (Hoboken)2010; 62: 881–887.
12.
JorgensenHSNakayamaHReithJRaaschouHOOlsenTS. Stroke recurrence: Predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology1997; 48: 891–895.
13.
BruceINUrowitzMBGladmanDDIbañezDSteinerG. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum2003; 48: 3159–3167.
14.
de SouzaAWSilvaNPde CarvalhoJFD’AlmeidaVNogutiMASatoEI. Impact of hypertension and hyperhomocystenemia on arterial thrombosis in primary antiphospholipid syndrome. Lupus2007; 16: 782–787.
15.
SciasciaSSannaGKhamashtaMA. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review. Ann Rheum Dis2015; 74: 2028–2033.
16.
PetriMRheinschmidtMWhiting-O’KeefeQ. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med1987; 106: 524–531.
17.
HanlyJGUrowitzMBSuL. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis2011; 70: 1726–1732.
18.
SannaGD’CruzDCuadradoMJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am2006; 32: 465–490.
19.
OostingJDDerksenRHBlokzijlLSixmaJJde GrootPG. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity – studies in a thrombosis model. Thromb Haemost1992; 68: 278–284.
20.
MeroniPLTincaniASeppN. Endothelium and the brain in CNS lupus. Lupus2003; 12: 919–928.
21.
ConnorPHuntBJ. Cerebral haemostasis and antiphospholipid antibodies. Lupus2003; 12: 929–934.
22.
SacréKBrihayeBHyafilF. Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: A controlled cardiac magnetic resonance imaging study. Arthritis Rheum2010; 62: 2093–2100.
23.
MikdashiJHandwergerBLangenbergPMillerMKittnerS. Baseline disease activity, hyperlipidemia and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke2007; 38: 281–285.
24.
FischerUBaumgartnerAArnoldM. What is a minor stroke?Stroke2010; 41: 661–666.
25.
WardMM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum1999; 42: 338–346.
26.
ChiuCHuangCCChanWL. Increased risk of ischemic stroke in patients with systemic lupus erythematosus: A nationwide population-based study. Intern Med2012; 51: 17–21.
27.
BreyRLStallworthCLMcGlassonDL. Antiphospholipid antibodies and stroke in young women. Stroke2002; 33: 2396–2400.
28.
LevineSRBreyRLTilleyBC. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA2004; 291: 576–584.
CerveraRBoffaMCKhamasthaMAHughesGR. The Euro-Phospholipid Project: Epidemiology of the antiphospholipid syndrome in Europe. Lupus2009; 18: 889–893.
31.
FrancesCPapoTWechslerBLaporteJLBiousseVPietteJC. Sneddon syndrome with or without antiphospholipid antibodies: A comparative study in 46 patients. Medicine1999; 78: 209–219.
32.
FrancèsCPietteJC. The mystery of Sneddon syndrome: Relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun2000; 15: 139–143.
33.
LiouTHHuangSWLinJWChangYSWuCWLinHW. Risk of stroke in patients with rheumatism: A nationwide longitudinal population-based study. Sci Rep2014; 4: 5110–5110.
34.
GovoniMBortoluzziAPadovanM. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun2016; 74: 41–72.
35.
WangIKMuoCHChangYC. Risks, subtypes and hospitalization costs of stroke among patients with systemic lupus erythematosus: A retrospective cohort study in Taiwan. J Rheumatol2012; 39: 1611–1618.
36.
ChangYSLiuCJChenWS. Increased risk of subarachnoid hemorrhage in patients with systemic lupus erythematosus: A nationwide population-based study. Arthritis Care Res2013; 65: 601–606.
37.
ZöllerBLiXSundquistJSundquistK. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: A nationwide follow-up study from Sweden. BMC Neurol2012; 12: 41–41.
38.
TornéRRodríguez-HernándezABernardTArikan AbellóFVilalta CastanJSahuquilloJ. Subarachnoid hemorrhage in systemic lupus erythematosus: Systematic review and report of three cases. Clin Neurol Neurosurg2015; 128: 17–24.
39.
NishidaHWakidaKSakuraiT. Cerebral venous thrombosis as a complication of neuropsychiatric systemic lupus erythematosus. Intern Med2015; 54: 837–841.
40.
FazekasFRopeleSSchmidtR. Can small-vessel disease-related cerebral abnormalities be used as a surrogate marker for vascular dementia trials?J Neural Transm Suppl2002; 62: 61–67.
41.
WisemanSJBastinMEJardineCL. Cerebral small vessel disease burden is increased in systemic lupus erythematosus. Stroke2016; 47: 2722–2728.
42.
ArvanitakisZBreyRLRandJH. Relation of antiphospholipid antibodies to postmortem brain infarcts in older persons. Circulation2015; 131: 182–189.
43.
BertsiasGIoannidisJPBoletisJ. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis2008; 67: 195–205.
44.
PexmanJHBarberPAHillMD. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol2001; 22: 1534–1542.
45.
SchlaugGBenfieldABairdAE. The ischemic penumbra: Operationally defined by diffusion and perfusion MRI. Neurology1999; 53: 1528–1537.
46.
DemaerelPDe RuyterNMaesFVelgheBWilmsG. Magnetic resonance angiography in suspected cerebral vasculitis. Eur Radiol2004; 14: 1005–1012.
47.
KatoRSumitomoSKawahataK. Successful treatment of cerebral large vessel vasculitis in systemic lupus erythematosus with intravenous pulse cyclophosphamide. Lupus2015; 24: 880–884.
48.
MajdakMRVuletićV. Thrombolysis for acute stroke in patient with systemic lupus erythematosus: A case report. J Neurol Sci2016; 361: 7–8.
49.
StadlerKMutzenbachJSKalssG. Therapeutic challenges after successful thrombectomy in a patient with an antiphospholipid syndrome associated M1-occlusion: A case report. Interv Neuroradiol2015; 21: 598–602.
50.
KhamashtaMACuadradoMJMujicF. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med1995; 332: 993–997.
51.
Ruiz-IrastorzaGHuntBJKhamasthaMA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum2007; 15: 1487–1495.
52.
CrowtherMAGinsbergJSJulianJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med2003; 349: 1133–1138.
53.
FinazziGMarchioliRBrancaccioV. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost2005; 3: 848–853.
54.
BorbaEFBonfáE. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol2001; 28: 780–785.
55.
MeroniPLRaschiETestoniC. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glyprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum2001; 44: 2870–2878.
56.
SchanbergLESandborgCBarnhartHX. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum2012; 64: 285–296.
57.
PetriMAKianiANPostWChristopher-StineLMagderLS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis2011; 70: 760–765.
